Protagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift

Simply Wall St.05:31

In August 2026, Protagonist Therapeutics reported a sharp swing to profitability, posting second-quarter net income of US$162.85 million and diluted earnings per share from continuing operations of US...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660910822?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-17 05:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660910822","market":"us","top_or_hot":-1,"title":"Protagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift","media":"Simply Wall St.","content":"<div>\n<p>In August 2026, Protagonist Therapeutics reported a sharp swing to profitability, posting second-quarter net income of US$162.85 million and diluted earnings per share from continuing operations of US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-is-up-63-after-swing-to-q2-pro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-17 05:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-is-up-63-after-swing-to-q2-pro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In August 2026, Protagonist Therapeutics reported a sharp swing to profitability, posting second-quarter net income of US$162.85 million and diluted earnings per share from continuing operations of US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-is-up-63-after-swing-to-q2-pro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTGX","symbol_name":"Protagonist Therapeutics Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-is-up-63-after-swing-to-q2-pro","article_id":"2660910822","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-is-up-63-after-swing-to-q2-pro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660910822","pubTimestamp":1786915862,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In August 2026, Protagonist Therapeutics reported a sharp swing to profitability, posting second-quarter net income of US$162.85 million and diluted earnings per share from continuing operations of US$2.29, compared with a loss a year earlier.\nAlongside this earnings turnaround, the company continued to utilize employee stock ownership plan shelf registrations, highlighting ongoing equity-based compensation as a meaningful part of its capital structure.\nWith this earnings reversal now on the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTGX":"Protagonist Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Protagonist Therapeutics (PTGX) 在第二季度盈利能力和员工持股计划使用转变后上涨 6.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTGX":1.5},"content_text":"In August 2026, Protagonist Therapeutics reported a sharp swing to profitability, posting second-quarter net income of US$162.85 million and diluted earnings per share from continuing operations of US$2.29, compared with a loss a year earlier. Alongside this earnings turnaround, the company continued to utilize employee stock ownership plan shelf registrations, highlighting ongoing equity-based compensation as a meaningful part of its capital structure. With this earnings reversal now on the table, we’ll explore how Protagonist Therapeutics’ new profitability profile shapes its investment narrative. AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementWhat Is Protagonist Therapeutics' Investment Narrative?For Protagonist Therapeutics, the big picture now hinges on whether its emerging commercial story can keep pace with its scientific one. The sharp swing to profitability in the latest quarter, helped by collaboration economics, strengthens the balance sheet ahead of the key rusfertide FDA decision in Q3 2026, which remains the dominant short term catalyst. At the same time, the cluster of employee stock ownership plan shelf registrations underlines that ongoing equity issuance is part of the model and could gradually weigh on per share metrics if not matched by sustained operating performance. With the share price already up strongly over the past year, the recent earnings surprise may already be partly reflected, so investors are likely to focus more closely on regulatory timing, commercialization execution with Takeda and how recurring those profits really are. However, investors should be aware of how ongoing ESOP issuance might affect per share outcomes.\n\nProtagonist Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesPTGX 1-Year Stock Price Chart Two fair value views from the Simply Wall St Community span roughly US$165 to very large numbers, underscoring how far apart expectations sit. Set that against the recent profit swing and looming rusfertide decision, and it is clear you are weighing very different scenarios for how durable this earnings story could become.Explore 2 other fair value estimates on Protagonist Therapeutics - why the stock might be worth just $165.31!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Protagonist Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Protagonist Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Protagonist Therapeutics' overall financial health at a glance.Seeking Other Investments?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.Uncover the next big thing with 20 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660910822","isCrawlerRequest":true}